Carnosine Supplementation Has No Effect on Inflammatory Markers in Adults with Prediabetes and Type 2 Diabetes: A Randomised Controlled Trial.

Saadati S, de Courten M, Deceneux C, Plebanski M, Scott D, Mesinovic J, Jansons P, Aldini G, Cameron J, Feehan J, Mousa A, de Courten B

Nutrients15 Nov 2024Cited by 6 (Europe PMC)

PMID39599686PMCIDPMC11597812DOI10.3390/nu16223900PepBankPUB-39599686

Download PDF PubMedAsk about this study

Jump to 10 results

Summary

Background/objectivesIn vitro studies suggest that carnosine reduces inflammation by upregulating anti-inflammatory mediators and downregulating pro-inflammatory cytokines. However, human clinical trials examining the effects of carnosine on inflammatory biomarkers are scant. We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).MethodsOut of 88 participants who were recruited, 49 adults with prediabetes or well-controlled T2D (HbA1c: 6.6 ± 0.7% [mean ± SD]) who were treated with diet and/or metformin were eligible for inclusion. Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks. We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks. The trial was registered at clinicaltrials.gov (NCT02917928).ResultsForty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial. After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all). The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).ConclusionsIn individuals with prediabetes and well-controlled T2D, carnosine supplementation did not result in any significant changes in inflammatory markers. Larger RCTs with longer follow-up durations are needed to evaluate whether carnosine may be beneficial in individuals with poorly controlled T2D.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, MCP-1 changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, MCP-1 changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeMCP-1
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968601
02HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, IL-6 changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, IL-6 changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeIL-6
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968602
03HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, IL-10 changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, IL-10 changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeIL-10
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968603
04HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, CRP changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, CRP changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeCRP
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968604
05HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, TNF-alpha changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, TNF-alpha changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeTNF-alpha
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968605
06HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, adiponectin changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, adiponectin changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeAdiponectin
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968606
07HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, leptin changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, leptin changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeLeptin
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968607
08HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, adipsin changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, adipsin changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeAdipsin
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968608
09HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, serpin changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, serpin changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeSerpin
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968609
10HumanRandomized controlled trialEfficacy outcome
In adults with prediabetes or well-controlled T2D, resistin changes did not differ between carnosine and placebo.
In plain wordsIn adults with prediabetes or well-controlled diabetes, resistin changes did not significantly differ between carnosine and placebo.
Peptide
L-carnosine
Outcome
No significant changeResistin
Study
n = 41
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Metabolic and weight
Studied dose
2 g/day · 14 weeksAs given in this study (human).
Source sentences
Summary
After 14 weeks of supplementation, changes in pro- and anti-inflammatory cytokine and adipokine levels did not differ between the carnosine and placebo groups (p > 0.05 for all).
5 context sentences(design, population, supporting numbers)
Summary · context
We measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.
Summary · context
The results remained unchanged after adjustment for confounders including age, sex, and anthropometric measures (e.g., body fat percentage and visceral adipose tissue).
Summary · context
We conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).
Summary · context
Participants were randomised to receive 2 g/day of carnosine or a matching placebo for 14 weeks.
Summary · context
Forty-one participants (M = 29/F = 12) aged 53 (42.6, 59.3) years [median (IQR)] completed the trial.
Show in the study text Report a problemFND-3959968610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT02917928

The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health

Monash Universityn = 40Oct 2016 to est. Jul 2023

Poor Glycemic Control · Cardiovascular Risk Factors · Cognitive Function 1, Social

Trial page ClinicalTrials.govUpdated 28 Jun 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.